AIC, a division of AIS Healthcare, has enriched its portfolio of infusion therapies by offering GLASSIA and ARALAST NP, both products of Takeda, for adult patients with emphysema tied to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency). The nationally accredited home infusion teams of AIC work harmoniously with physicians to offer tailored infusion services to patients, either in their homes or at infusion suite settings, thereby enhancing accessibility and convenience for those requiring these treatments.
Jud Hall, President of AIC, expressed enthusiasm for incorporating Takeda’s Alpha1 therapies into AIC’s offering, highlighting the broadened spectrum of treatment options now available to patients with alpha1-antitrypsin deficiency. GLASSIA, approved by the FDA in 2010, and ARALAST NP, approved in 2002, serve as Alpha1-Proteinase Inhibitors (Human) (Alpha1-PI) designed for chronic augmentation therapy in adults with emphysema due to a severe deficiency of Alpha1-PI. Although the definitive impact of these augmentation therapies on pulmonary exacerbations and the progression of emphysema in patients with Alpha1-PI deficiency is yet to be conclusively proven through randomized clinical trials, these treatments represent hope for many facing this condition.
GLASSIA and ARALAST NP are accessible across all AIC locations, ensuring patients nationwide can benefit from AIC’s comprehensive care model. This model includes 24/7 access to clinical and support staff, a personalized care team composed of clinical pharmacists, home infusion nurses, RN clinical review specialists, and patient onboarding specialists to guide patients through their treatment journey.
AIC stands out not only for its quality of patient care but also for its operational excellence. It holds dual accreditations from URAC and the Accreditation Commission for Health Care (ACHC). This recognition underscores AIC’s commitment to maintaining the highest standards in healthcare delivery.
As AIS Healthcare continues its mission to advance quality and improve lives, adding GLASSIA and ARALAST NP to AIC’s therapeutic options solidifies its role as a leading provider of targeted drug delivery and infusion care solutions. For more detailed information about AIC’s services, healthcare providers are encouraged to contact AIC representatives or visit the AIS Healthcare website.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
